Home  »  Technologies   »  Terns Pharmaceuticals Inc. Is A Buy Small Cap Stoc...

Terns Pharmaceuticals Inc. Is A Buy Small Cap Stock: Analysts

Terns Pharmaceuticals Inc. (NASDAQ:TERN) has seen 1.53 million shares traded in the recent trading session. The company, currently valued at $218.75M, closed the recent trade at $6.09 per share which meant it gained $0.41 on the day or 7.22% during that session. The TERN stock price is -35.96% off its 52-week high price of $8.28 and 76.19% above the 52-week low of $1.45. If we look at the company’s 10-day average daily trading volume, we find that it stood at 76740.0 shares traded. The 3-month trading volume is 163.24K shares.

The consensus among analysts is that Terns Pharmaceuticals Inc. (TERN) is an Overweight stock at the moment, with a recommendation rating of 2.50. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 2 out of 4 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$0.52.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Terns Pharmaceuticals Inc. (NASDAQ:TERN) trade information

Sporting 7.22% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, 11/22/22 when the TERN stock price touched $6.09 or saw a rise of 4.84%. Year-to-date, Terns Pharmaceuticals Inc. shares have moved -19.66%, while the 5-day performance has seen it change 20.59%. Over the past 30 days, the shares of Terns Pharmaceuticals Inc. (NASDAQ:TERN) have changed -14.33%. Short interest in the company has seen 0.43 million shares shorted with days to cover at 2.18.

Wall Street analysts have a consensus price target for the stock at $7.00, which means that the shares’ value could jump 13.0% from the levels at last check today. The projected low price target is $6.00 while the price target rests at a high of $9.00. In that case, then, we find that the latest price level in today’s session is -47.78% off the targeted high while a plunge would see the stock lose 1.48% from the levels at last check today.

Terns Pharmaceuticals Inc. (TERN) estimates and forecasts

Figures show that Terns Pharmaceuticals Inc. shares have underperformed across the wider relevant industry. The company’s shares have gained 271.24% over the past 6 months, with this year growth rate of 2.71%, compared to 4.60% for the industry. Other than that, the company has, however, increased its growth outlook for the 2022 fiscal year revenue. Growth estimates for the current quarter are -10.60% and 3.60% for the next quarter.

TERN Dividends

Terns Pharmaceuticals Inc. is expected to release its next earnings report between November 14 and November 18 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

Terns Pharmaceuticals Inc. (NASDAQ:TERN)’s Major holders

Insiders own 4.42% of the company shares, while shares held by institutions stand at 84.99% with a share float percentage of 88.92%. Investors are also buoyed by the number of investors in a company, with Terns Pharmaceuticals Inc. having a total of 71 institutions that hold shares in the company. The top two institutional holders are Orbimed Advisors LLC. with over 3.79 million shares worth more than $9.4 million. As of Jun 29, 2022, Orbimed Advisors LLC. held 14.95% of shares outstanding.

The other major institutional holder is Vivo Capital, LLC, with the holding of over 2.68 million shares as of Jun 29, 2022. The firm’s total holdings are worth over $6.63 million and represent 10.55% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and iShares NASDAQ Biotechnology ETF. As of Jun 29, 2022, the former fund manager holds about 0.97% shares in the company for having 0.25 million shares of worth $0.61 million while later fund manager owns 0.13 million shares of worth $0.74 million as of Sep 29, 2022, which makes it owner of about 0.49% of company’s outstanding stock.

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts